|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/70 | (2006.01) |
| A61P 3/10 | (2006.01) | ||
| A61K 9/16 | (2006.01) | ||
| A61K 9/20 | (2006.01) |
| (11) | Number of the document | 2508188 |
| (13) | Kind of document | T |
| (96) | European patent application number | 12153939.9 |
| Date of filing the European patent application | 2008-03-21 | |
| (97) | Date of publication of the European application | 2012-10-10 |
| (45) | Date of publication and mention of the grant of the patent | 2023-05-10 |
| (46) | Date of publication of the claims translation | 2023-07-25 |
| (30) | Number | Date | Country code |
| 896286 P | 2007-03-22 | US |
| (72) |
Bindra, Dilbir , US
Dali, Mandar V. , US
Parab, Prakash V. , US
Patel, Jatin M. , US
Tao, Li , US
Tejwani, Ravindra W. , US
Vatsaraj, Nipa , US
Wu, Yongmei , US
|
| (73) |
AstraZeneca AB ,
151 85 Södertälje,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Farmacinės vaisto formos, kurių sudėtyje yra dapagliflozino propilenglikolio hidratas |
| Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate |
| Payment date | Validity (years) | Amount | |
| 2025-02-18 | 18 | 347.00 EUR |
| 2026-03-21 |